Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 27, 2006

View Archived Issues

Treatment-related anemia, hypersensitivity addressed at gastrointestinal cancer congress

Zenyth Therapeutics recaps recent highlights

Lee's to begin clinical testing of Declotana in China

MediWound begins phase III trials for wound healing product

Norwood Immunology begins phase II study in autologous BMT cancer patients

NICE recommends Pegasys for first-line treatment of chronic hepatitis B

Actilon begins new phase II study in chronic hepatitis C infection

Study results further support utility of Niaspan

Inotek advances IMS into phase I study

Enrollment ceased in Genzyme's phase II cardiac cell therapy study

PTHrP-positive primary breast tumors are less invasive and associated with improved survival

IKK represents a potential target for melanoma therapy

Monogram Biosciences collaborates with Merck on phase III trials of MK-0518

Recent Gruenenthal patent reports novel analgesic agents

Agents with potential utility in the treatment of metabolic disorders described in recent patents

Preclinical update of SLV-308 presented at 1st World Parkinson Congress

CpG-7909 may be an effective adjuvant to anthrax vaccine

VaxGen presents preclinical and clinical data on their attenuated smallpox vaccine LC16m8

CHMP recommends European approval of Preotact

European CHMP hands down positive opinion for Erbitux in head & neck cancer

Pramipexole recommended for approval in E.U. for restless legs syndrome

BioPartners receives positive Europe opinion for Valtropin

Fast track status for tolvaptan in autosomal dominant polycystic kidney disease

Positive European opinion for Evoltra in relapsed or refractory pediatric ALL

Approvable letter for zoledronic acid in Paget's disease

DuoTrav eye drops recommended for approval in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...